Characterization of Angiotensin-Converting Enzyme Inhibitory Activity

Subscriber access provided by READING UNIV

Bioactive Constituents, Metabolites, and Functions

Characterization of Angiotensin-Converting Enzyme Inhibitory Activity of X-Hyp-Gly-Type Tripeptides: Importance of Collagen-Specific Prolyl Hydroxylation Yuki Taga, Osamu Hayashida, Ahmed Ashour, Yhiya Amen, Masashi Kusubata, Kiyoko Ogawa-Goto, kuniyoshi shimizu, and Shunji Hattori J. Agric. Food Chem., Just Accepted Manuscript • DOI: 10.1021/acs.jafc.8b03648 • Publication Date (Web): 31 Jul 2018 Downloaded from http://pubs.acs.org on August 4, 2018

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 27

Journal of Agricultural and Food Chemistry

Characterization of Angiotensin-Converting Enzyme Inhibitory Activity of X-Hyp-GlyType Tripeptides: Importance of Collagen-Specific Prolyl Hydroxylation

Yuki Taga,*,† Osamu Hayashida,† Ahmed Ashour,‡,§ Yhiya Amen,‡,§ Masashi Kusubata,† Kiyoko Ogawa-Goto,† Kuniyoshi Shimizu,‡ and Shunji Hattori†

†

Nippi Research Institute of Biomatrix, 520-11 Kuwabara, Toride, Ibaraki 302-0017, Japan

‡

Faculty of Agriculture, Kyushu University, 6-10-1 Hakozaki, Higashi-ku, Fukuoka 812-8581,

Japan §

Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura 35516,

Egypt

To whom correspondence should be addressed: Yuki Taga Nippi Research Institute of Biomatrix, 520-11 Kuwabara, Toride, Ibaraki 302-0017, Japan Tel: +81-297-71-3046; Fax: +81-297-71-3041 E-mail: [email protected]

1

ACS Paragon Plus Environment


Page 2 of 27

1

ABSTRACT

2

Hydroxyproline (Hyp) is a collagen-specific amino acid formed by post-translational

3

hydroxylation of Pro residues. Various Hyp-containing oligopeptides are transported into the

4

blood at high concentrations after oral ingestion of collagen hydrolysate. Here we investigated

5

the angiotensin-converting enzyme (ACE) inhibitory activity of X-Hyp-Gly-type tripeptides. In

6

an in vitro assay, ginger-degraded collagen hydrolysate enriched with X-Hyp-Gly-type

7

tripeptides dose-dependently inhibited ACE, and various synthetic X-Hyp-Gly-type tripeptides

8

showed ACE-inhibitory activity. In particular, strong inhibition was observed for Leu-Hyp-Gly,

9

Ile-Hyp-Gly, and Val-Hyp-Gly with IC50 values of 5.5, 9.4, and 12.8 µM, respectively.

10

Surprisingly, substitution of Hyp with Pro dramatically decreased inhibitory activity of X-Hyp-

11

Gly, indicating that Hyp is important for ACE inhibition. This finding was supported by

12

molecular docking experiments using Leu-Hyp-Gly/Leu-Pro-Gly. We further demonstrated that

13

prolyl hydroxylation significantly enhanced resistance to enzymatic degradation by incubation

14

with mouse plasma. The strong ACE-inhibitory activity and high stability of X-Hyp-Gly-type

15

tripeptides highlight their potential for hypertension control.

16 17

Keywords: collagen hydrolysate, hydroxyproline, X-Hyp-Gly, ginger, angiotensin-converting

18

enzyme

2


Page 3 of 27

19


INTRODUCTION

20

Collagen is the most common protein in the body and is particularly abundant in connective

21

tissues, such as skin, bone, and tendon. Features of the amino acid sequence of collagen are

22

repeating Gly-Xaa-Yaa triplets and numerous post-translational modifications catalyzed by

23

specific enzymes before triple helix formation in the endoplasmic reticulum.1 Most Pro residues

24

lying at the Yaa position are hydroxylated to 4-hydroxyproline (4-Hyp) (~100 residues/1000

25

amino acid residues in type I collagen), contributing to the stabilization of the collagen triple

26

helix.2 Other collagen-specific post-translational modifications, including prolyl hydroxylation at

27

the Xaa position forming 3-Hyp and lysyl hydroxylation/glycosylation at the Yaa position, are

28

rare compared to 4-Hyp (hereinafter simply referred to as Hyp).3

29

Oral ingestion of collagen hydrolysates prepared by enzymatic hydrolysis of gelatin has shown

30

various beneficial effects, such as increasing bone density,4, 5 modulating lipid metabolism,6, 7

31

lowering blood sugar levels,8,

32

oligopeptides were identified in blood at markedly high concentrations after oral ingestion of

33

collagen hydrolysate.14 The total concentration of Hyp-containing oligopeptides reaches 100 µM

34

in the blood after the ingestion,15,

35

conferred by the presence of Hyp within the peptide sequence.14, 17-19 Various Hyp-containing

36

peptides appear in the blood, including Pro-Hyp, Hyp-Gly, and X-Hyp-Gly-type tripeptides.14, 16-

37

18, 20

38

oligopeptides, such as growth stimulation of skin fibroblasts,17,

39

differentiation,23, 24 and improvement of skin barrier dysfunction.25

9

and lowering blood pressure.10-13 In 2005, Hyp-containing

16

probably due to their high peptidase/protease resistance

Recent studies have demonstrated physiological activities of these collagen-specific 21, 22

promotion of osteoblast

40

Angiotensin-converting enzyme (ACE) is a dipeptidyl carboxypeptidase that converts an

41

inactive form of decapeptide, angiotensin I, into a potent vasoconstrictor, angiotensin II.26 This 3



Page 4 of 27

42

enzyme also catalyzes inactivation of a vasodilator, bradykinin. Therefore, inhibition of ACE is a

43

major target for the prevention and treatment of hypertension. A wide variety of food proteins

44

have been reported as a source of ACE-inhibitory peptides.26, 27 For example, well-established

45

ACE-inhibitory peptides, Val-Pro-Pro and Ile-Pro-Pro, were isolated from sour milk and

46

demonstrated to decrease blood pressure after oral administration.28, 29 To date, various types of

47

enzymatic hydrolysates of collagen have been discovered to possess ACE-inhibitory activity and

48

in vivo antihypertensive effects.10-13,

49

peptides was determined in some studies, such as Gly-Pro-Leu,30, 31 Gly-Pro-Met,30 Gly-Pro-

50

Val,31 Met-Gly-Pro,13 and Val-Gly-Pro-Val.32 In addition, Hyp-containing peptides possessing

51

high ACE-inhibitory activity were identified in chicken breast muscle hydrolysate (Gly-Phe-

52

Hyp-Gly-Thr-Hyp-Gly-Leu-Hyp-Gly-Phe) and chicken leg collagen hydrolysate (Gly-Ala-Hyp-

53

Gly-Leu-Hyp-Gly-Pro).11, 33

30, 31

The structure of collagen-derived ACE-inhibitory

54

We recently developed a novel type of collagen hydrolysate using ginger protease.18 The

55

unique substrate specificity of ginger protease recognizing Pro and Hyp at the P2 position enables

56

efficient generation of X-Hyp-Gly-type tripeptides, which are almost undetectable in

57

commercially available collagen hydrolysates. Although X-Hyp-Gly-type tripeptides appear in

58

blood at high concentrations after oral ingestion regardless of the types of collagen hydrolysates,

59

the ginger-degraded collagen hydrolysate (GDCH) shows more higher absorption of this type of

60

tripeptide.18 Iwai et al. investigated the ACE-inhibitory activity of Hyp-containing peptides

61

detected in human blood after oral intake of chicken collagen hydrolysate, such as Ala-Hyp (IC50

62

= 0.177 mM) and Pro-Hyp (IC50 = 18.118 mM).34 The IC50 value against ACE was also

63

measured for some X-Hyp-Gly-type tripeptides (0.601 mM for Ser-Hyp-Gly, 0.711 mM for Ala-

64

Hyp-Gly, 1.129 mM for Pro-Hyp-Gly, and 82.330 mM for Glu-Hyp-Gly).34 The inhibitory 4


Page 5 of 27


65

activity of X-Hyp-Gly-type tripeptides was moderate in their study. However, in the current

66

study, we found that X-Hyp-Gly-type tripeptides where X is branched-chain aliphatic amino

67

acids strongly inhibit ACE. We also showed that Hyp is a contributing factor to the ACE-

68

inhibitory activity of X-Hyp-Gly.

69 70

MATERIALS AND METHODS

71

Chemicals. ACE from porcine kidney and hippuric acid (Hip) were purchased from Sigma-

72

Aldrich (St. Louis, MO, USA). Hippuryl-histidyl-leucine (HHL) was purchased from Peptide

73

Institute (Osaka, Japan), and N-benzoyl-d5-glycine (d5-Hip) was purchased from CDN Isotopes

74

(Quebec, Canada). Gly-Ala-Hyp (>99% purity), Ala-Pro-Gly (>99% purity), and Ile-Pro-Pro

75

(>98% purity) were purchased from Bachem (Bubendorf, Switzerland), and other peptides

76

(>95% purity) were custom synthesized by AnyGen (Kwangju, Korea).

77 78

Ethics Statement. All animal studies were approved by the Experimental Ethical Committee of Nippi Research Institute of Biomatrix.

79

Preparation of Collagen Hydrolysates. GDCH was prepared from bovine bone gelatin using

80

ginger protease as reported previously,18 with a slight modification for industrial production.

81

GDCH was heated at 81 °C and pH 5.5 for 6 h to prepare heat-treated GDCH (H-GDCH). The

82

collagen hydrolysates were dissolved in 0.1% formic acid for liquid chromatography–mass

83

spectrometry (LC–MS) analysis of oligopeptides.

84

ACE Inhibition Assay. ACE-inhibitory activity of collagen hydrolysates and synthetic

85

peptides was measured as reported previously with some modifications.35, 36 Peptide samples at

86

varied concentrations were pre-incubated with ACE in 75 mM Tris-HCl (pH 8.3) at 37 °C for 10

5



Page 6 of 27

87

min, and the reaction was started by adding HHL as a substrate. The final concentrations of ACE

88

and HHL in the reaction mixture were 1 mU/mL and 0.1 mM, respectively. Aliquots were taken

89

at 5, 10, 20, and 30 min during incubation at 37 °C, and an equal volume of 1% formic acid

90

containing d5-Hip was added to stop the reaction. An external calibration curve was prepared

91

using a standard of Hip after mixing with an equal volume of 1% formic acid containing d5-Hip.

92

Hip was quantified by LC–MS in multiple reaction monitoring (MRM) mode using a hybrid

93

triple quadrupole/linear ion trap 3200 QTRAP mass spectrometer (AB Sciex, Foster City, CA)

94

coupled to an Agilent 1200 Series HPLC system (Agilent Technologies, Palo Alto, CA).

95

Samples were loaded onto an Ascentis Express C18 HPLC column (5 µm particle size, L × I.D.

96

150 mm × 2.1 mm; Supelco, Bellefonte, PA) at a flow rate of 500 µL/min and separated by a

97

binary gradient as follows: 100% solvent A (0.1% formic acid) for 2 min, linear gradient of 0–

98

70% solvent B (100% acetonitrile) for 4 min, 90% solvent B for 2 min, and 100% solvent A for

99

2 min. The MRM transitions of Hip and d5-Hip were m/z 180.2→105.2 and m/z 185.2→110.2,

100

respectively, with collision energy of 17 V. Concentrations of liberated Hip in test samples were

101

estimated using the external calibration curve with correction using d5-Hip.

102

Enzymatic activity of ACE was calculated from the time course of the liberated Hip

103

concentration (nmol/min), and inhibitory activity was calculated from the ACE activity of the

104

sample and blank control as follows: inhibitory activity (%) = 100 × (blank − sample)/blank. The

105

IC50 value was determined by plotting the logarithm of ACE-inhibitory activity against peptide

106

sample concentration.

107

The mode of ACE inhibition and Ki value were determined by Dixon plot37 under the same

108

reaction conditions with two substrate concentrations of 0.1 and 1.0 mM. Three peptide

6


Page 7 of 27


109

concentrations were used for the reaction (0, 1.9, and 4.7 µM for Leu-Hyp-Gly and 0, 50.1, and

110

125.2 µM for Leu-Pro-Gly).

111

Peptide Degradation Using Mouse Plasma. The experiment was performed as reported

112

previously.18 In brief, a synthetic tripeptide mixture (Ala-Hyp-Gly, Leu-Hyp-Gly, Ala-Pro-Gly,

113

Leu-Pro-Gly, and Ile-Pro-Pro) was incubated with fresh plasma prepared from male ICR mice

114

(15 weeks of age; Japan SLC, Shizuoka, Japan) at a concentration of 20 µg/mL each at 37 °C.

115

Time-course samples were collected at 0, 15, 30, 60, and 90 min during the incubation. The

116

reactants were deproteinized by adding three volumes of ethanol, and the ethanol-soluble

117

fractions were diluted with 0.1% formic acid for LC–MS analysis.

118

LC–MS Analysis of Oligopeptides. We quantified oligopeptides in collagen hydrolysates and

119

peptide degradation samples by LC–MS in MRM mode. Sample separation was performed using

120

an Ascentis Express F5 HPLC column (5 µm particle size, L × I.D. 250 mm × 4.6 mm; Supelco)

121

at a flow rate of 400 µL/min with a binary gradient as follows: 100% solvent A (0.1% formic

122

acid) for 7.5 min, linear gradient of 0–90% solvent B (100% acetonitrile) for 12.5 min, 90%

123

solvent B for 5 min, and 100% solvent A for 5 min. The MRM transitions of the oligopeptides

124

are shown in Table S1.

125

Molecular docking. A molecular binding experiment was designed to predict the binding

126

mode of Leu-Hyp-Gly and Leu-Pro-Gly at the active sites of ACE. The crystal structure of ACE

127

was downloaded from the Protein Data Bank (www.rcsb.org; access code 4CA5)38 and then

128

imported into the work place of the software AutoDock Vina implemented in PyRx.39 The ligand

129

with the most favorable binding energy (increasingly negative value) was considered a potential

130

inhibitor.

131

7



132

Page 8 of 27

RESULTS

133

ACE-Inhibitory Activity of Collagen Hydrolysates Prepared Using Ginger Protease. We

134

used two types of collagen hydrolysates for the ACE inhibition assay. GDCH was prepared by

135

enzymatic hydrolysis of bovine gelatin using ginger protease, and GDCH was further subjected

136

to heat treatment at 81 °C for 6 h to prepare H-GDCH. The contents of X-Hyp-Gly- and X-Pro-

137

Gly-type-tripeptides in these collagen hydrolysates are shown in Table 1. Consistent with

138

previous observations,18, 40, 41 we detected substantial amounts of various X-Hyp-Gly in GDCH.

139

Pro-Hyp-Gly was only slightly generated because ginger protease cannot cleave the Gly-Pro

140

bond.18 We also detected small amounts of X-Pro-Gly originating from partial hydroxylation of

141

Pro residues. In contrast, all X-Hyp-Gly-type tripeptides were significantly diminished in H-

142

GDCH due to efficient cyclization into cyclo(X-Hyp) through heating as reported recently.40

143

Similar heat-induced decreases were also observed for X-Pro-Gly, probably due to conversion

144

into cyclo(X-Pro). Gly-Pro-Y-type tripeptides, which are another major type of oligopeptides in

145

GDCH, were only slightly decreased by the heat treatment (data not shown) as reported

146

previously.41

147

We used LC–MS to detect Hip liberated from HHL by porcine kidney ACE for measurement of

148

ACE-inhibitory activity of the collagen hydrolysates. Figure 1 shows ACE inhibition curves of

149

GDCH and H-GDCH. Both collagen hydrolysates dose-dependently inhibited ACE activity, and

150

the IC50 value of GDCH (0.210 mg/mL) was markedly lower than that of H-GDCH (0.336

151

mg/mL). Since the most striking difference between GDCH and H-GDCH was the X-Hyp-Gly

152

content (Table 1), it was suggested that this type of Hyp-containing tripeptide has high ACE-

153

inhibitory activity.

8


Page 9 of 27


154

ACE-Inhibitory Activity of X-Hyp-Gly-Type Tripeptides. We investigated ACE-inhibitory

155

activity of X-Hyp-Gly using a series of synthetic peptides (Table 1). The IC50 value of Ile-Pro-

156

Pro used as a positive control was 0.9 µM. This was lower than a previously reported value (5

157

µM) estimated by a conventional method with UV detection of Hip,28 probably due to the low

158

substrate concentration achieved by sensitive LC–MS detection. Among the X-Hyp-Gly-type

159

tripeptides, Leu-Hyp-Gly most strongly inhibited ACE (IC50 = 5.5 µM). This ACE-inhibitory

160

activity was lower than, but not far from, that of the known ACE-inhibitory peptide, Ile-Pro-Pro.

161

In addition, higher ACE-inhibitory effects were also detected for Ile-Hyp-Gly and Val-Hyp-Gly

162

with IC50 values of 9.4 µM and 12.8 µM, respectively. Other X-Hyp-Gly-type tripeptides,

163

including Ala-Hyp-Gly, Glu-Hyp-Gly, Phe-Hyp-Gly, Pro-Hyp-Gly, and Ser-Hyp-Gly, displayed

164

moderate inhibition (IC50 = 130.6–404.5 µM). ACE-inhibitory activity of Leu-Pro-Gly was

165

extremely low (IC50 = 373.8 µM) compared to that of Leu-Hyp-Gly. Other X-Pro-Gly-type

166

tripeptides (X = Ala, Pro, Ser, and Val) also showed 5- to 10-fold decreases in ACE-inhibitory

167

activity compared to corresponding X-Hyp-Gly-type tripeptides. In contrast, ACE-inhibitory

168

activity of another type of Hyp-containing tripeptide, Gly-X-Hyp, was lower than that of

169

corresponding Gly-X-Pro-type tripeptides, showing 5- and 16-fold increases in IC50 values for

170

Gly-Ala-Hyp and Gly-Leu-Hyp, respectively (Table S2). A pronounced change was observed by

171

removing the C-terminal Gly residue from Leu-Hyp-Gly (IC50 = 3462.1 µM for Leu-Hyp).

172

We estimated the mode of ACE inhibition and Ki value for Leu-Hyp-Gly and Leu-Pro-Gly by

173

Dixon plot (Fig. 2). Both peptides were determined to be competitive inhibitors, and the Ki value

174

significantly differed between the peptides (5.5 µM for Leu-Hyp-Gly and 270.6 µM for Leu-Pro-

175

Gly). These values were close to their IC50 values against ACE.

176

Molecular docking 9



Page 10 of 27

177

Molecular docking is a computational procedure that is useful for predicting the optimal pose

178

and binding affinity of a ligand (tripeptide) when it interacts with a target protein (ACE) to form

179

a stable complex. Guided by the docking scores, it is noted that Leu-Hyp-Gly showed excellent

180

binding activity with a binding energy value of −7.7 kcal/mol compared to that of Leu-Pro-Gly

181

(−7.1 kcal/mol). Careful investigation of the interactions of Leu-Hyp-Gly with the target enzyme

182

indicated that the hydroxyl group showed strong binding interactions with the Tyr-523 residue of

183

the amino acid sequence of the binding site of ACE (Fig. S1), while the Tyr residue did not

184

interact with Leu-Pro-Gly (Fig. S2). These results could at least in part explain the superior

185

ACE-inhibitory activity of Leu-Hyp-Gly over that of Leu-Pro-Gly.

186

Stability of X-Hyp-Gly-Type Tripeptides in Mouse Plasma. We previously showed that Ala-

187

Hyp-Gly was highly stable as well as Pro-Hyp in mouse plasma, while Gly-Pro-Ala and Gly-

188

Ala-Hyp were rapidly degraded.18 The data suggested that X-Hyp-Gly is resistant to enzymatic

189

digestion due to the presence of Hyp located in the middle position. In the present study, we

190

similarly studied the stability of Ala-Hyp-Gly and Leu-Hyp-Gly by incubation with mouse

191

plasma using comparisons among Ala-Pro-Gly, Leu-Pro-Gly, and Ile-Pro-Pro. As shown in Fig.

192

3, Ala-Pro-Gly and Leu-Pro-Gly were completely degraded after incubation for 60 min, but

193

stability significantly increased for corresponding X-Hyp-Gly. Ala-Hyp-Gly remained

194

unchanged during the 90 min incubation, consistent with the previous observation.18 In addition,

195

Leu-Hyp-Gly exhibited only modest reduction comparable to Ile-Pro-Pro, which was reported to

196

have high resistance to enzymatic degradation.42 The high stability of X-Hyp-Gly-type

197

tripeptides would help exert their high ACE-inhibitory activity in vivo.

198 199

DISCUSSION 10


Page 11 of 27


200

In the present study, we demonstrated that X-Hyp-Gly-type tripeptides, especially of which X

201

is branched-chain aliphatic amino acids, have high ACE-inhibitory activity. It was clearly shown

202

that prolyl hydroxylation is critical for ACE inhibition by X-Hyp-Gly. Saiga et al. previously

203

identified Hyp-containing ACE-inhibitory peptides, including Gly-Phe-Hyp-Gly-Thr-Hyp-Gly-

204

Leu-Hyp-Gly-Phe (IC50 = 42.4 µM) and Gly-Ala-Hyp-Gly-Leu-Hyp-Gly-Pro (IC50 = 29.4 µM),

205

derived from chicken collagen.11,

206

antihypertensive effects against spontaneously hypertensive rats.43,

207

evidence that these peptides are transported into the blood in an intact form. We speculate that X-

208

Hyp-Gly-type tripeptides are generated by partial hydrolysis in the gastrointestinal tract and

209

blood and are main contributors to the antihypertensive effects. In fact, Leu-Hyp-Gly showing

210

the highest ACE-inhibitory activity is present both within the previously established Hyp-

211

containing antihypertensive peptides.

33

The two kinds of Hyp-containing peptides showed 44

However, there is no

212

Surprisingly, substitution of Hyp with Pro dramatically decreased the ACE-inhibitory activity

213

of X-Hyp-Gly regardless of the amino acid residue at the N-terminal. Alemán et al. investigated

214

the effect of Hyp on ACE-inhibitory activity using Gly-Pro-X-Gly-X-X-Gly-Phe-X-Gly-Pro-X-

215

Gly-X-Ser where X was either Leu or Hyp.45 While higher inhibition of ACE was observed when

216

all X were Leu, a corresponding peptide with X being Hyp did not show any inhibitory activity.

217

In contrast, Saiga et al. suggested the importance of Hyp for ACE inhibition by replacing all Hyp

218

within Gly-Phe-Hyp-Gly-Thr-Hyp-Gly-Leu-Hyp-Gly-Phe with Pro, which decreased the

219

inhibitory activity 10-fold.33 However, in a subsequent paper, they concluded that Phe at the C-

220

terminal most critically affects the ACE-inhibitory activity of the peptide.43 These previous data

221

were obtained for the relatively long peptides. In contrast, our findings are based on observations

222

of tripeptides, which would more directly reflect the effect of Hyp on ACE-inhibitory activity. In 11



Page 12 of 27

223

addition to X-Hyp-Gly-type tripeptides, we analyzed Gly-Ala-Hyp and Gly-Leu-Hyp with

224

comparison to Gly-Ala-Pro and Gly-Leu-Pro, which were previously reported to strongly inhibit

225

ACE.46, 47 The ACE-inhibitory activity was dramatically decreased by prolyl hydroxylation in the

226

case of this type of Hyp-containing tripeptide, indicating that the position of Hyp is also

227

important for the enhancement of ACE inhibition. Molecular docking experiments comparing

228

Leu-Hyp-Gly with Leu-Pro-Gly suggested that the hydroxyl group of Hyp contributes to the

229

ACE-inhibitory activity of X-Hyp-Gly through its interaction with the enzyme. However, further

230

studies using various types and lengths of Hyp-containing peptides are needed to clarify the

231

essential requirements for enhancement of ACE inhibition by prolyl hydroxylation.

232

Although a relationship between the peptide primary structure and ACE-inhibitory activity has

233

not been completely elucidated, common features can be found among ACE-inhibitory peptides;

234

for example, peptides having hydrophobic amino acids at terminal positions tend to show high

235

ACE inhibition.26, 48, 49 Among X-Hyp-Gly-type tripeptides, Leu-Hyp-Gly, Ile-Hyp-Gly, and Val-

236

Hyp-Gly exhibited especially strong ACE-inhibitory activity in this study. All of these peptides

237

have branched-chain aliphatic amino acids at the Xaa position. This is consistent with previous

238

observations that branched-chain aliphatic amino acids at the N-terminal are suitable for binding

239

to ACE.47-49 A dipeptide, Leu-Hyp, displayed extremely weak ACE-inhibitory activity that was

240

600-fold lower than that of Leu-Hyp-Gly, indicating that C-terminal Gly is also important for

241

ACE inhibition by X-Hyp-Gly-type tripeptides. Taken together, all constituents of X-Hyp-Gly

242

are indispensable to exert high ACE-inhibitory activity.

243

One of the advantages of collagen-derived Hyp-containing peptides is their high

244

bioavailability. While other food-derived ACE-inhibitory peptides, including Ile-Pro-Pro from

245

milk casein and Val-Tyr from sardine muscle, are detected in blood at nM levels after oral 12


Page 13 of 27


246

ingestion,50, 51 X-Hyp-Gly-type tripeptides show remarkably higher blood concentrations at µM

247

levels.15, 16 We consider that two factors contribute to the high bioavailability of X-Hyp-Gly. One

248

is that -X-Pro-Gly- sequences are frequently observed in collagen (Fig. S3). Since most Pro

249

residues at the Yaa position are hydroxylated, large amounts of X-Hyp-Gly are potentially

250

generated during production of collagen hydrolysate and in the gastrointestinal tract after oral

251

ingestion. In contrast, only one -Ile-Pro-Pro- sequence is present in bovine β- and κ-casein,

252

respectively, and bovine αs1- and αs2-casein do not have the sequence. Although Ile-Hyp-Gly and

253

Val-Hyp-Gly displayed higher ACE-inhibitory activity next to Leu-Hyp-Gly, their contents in

254

GDCH were small due to the low occurrence of -Ile-Pro-Gly- and -Val-Pro-Gly- sequences in

255

bovine type I collagen (Fig. S3). The use of other animal sources of collagen may increase the

256

yield of these peptides.

257

Another factor responsible for the high bioavailability of X-Hyp-Gly-type tripeptides is their

258

high resistance to peptidase/protease. A previous study reported that Val-Pro-Pro and Ile-Pro-Pro

259

were not very susceptible to digestive enzymes and Caco-2 cells expressing various brush-border

260

peptidases, suggesting that orally administered these antihypertensive tripeptides are absorbed

261

intact into the blood.42 We showed that Ile-Pro-Pro was stable but slightly decreased (~30%)

262

during incubation for 90 min with mouse plasma. Although Ala-Pro-Gly and Leu-Pro-Gly were

263

rapidly degraded, the stability of corresponding X-Hyp-Gly-type tripeptides was higher (Ala-

264

Hyp-Gly) or comparable (Leu-Hyp-Gly) to that of Ile-Pro-Pro. The high bioavailability of the

265

collagen-derived Hyp-containing peptides possessing high ACE-inhibitory activity highlights

266

their potential for hypertension control. Further in vivo experiments are warranted to evaluate the

267

antihypertensive effects of X-Hyp-Gly-type tripeptides and GDCH enriched with the peptides.

268

13



Page 14 of 27

269

ABBREVIATIONS USED

270

Hyp, hydroxyproline; ACE, angiotensin-converting enzyme; GDCH, ginger-degraded collagen

271

hydrolysate; Hip, hippuric acid; HHL, hippuryl-histidyl-leucine; H-GDCH, heat-treated ginger-

272

degraded collagen hydrolysate; LC–MS, liquid chromatography–mass spectrometry; MRM,

273

multiple reaction monitoring

274 275

Supporting Information. Figure S1: Molecular docking between Leu-Hyp-Gly and ACE.

276

Figure S2: Molecular docking between Leu-Pro-Gly and ACE. Figure S3: Amino acid

277

sequences of the triple helical region of bovine type I collagen. Table S1: MRM transitions of

278

dipeptides and tripeptides. Table S2: Effect of prolyl hydroxylation on ACE-inhibitory activity

279

of Gly-X-Pro-type tripeptides. This material is available free of charge via the Internet at

280

http://pubs.acs.org.

14


Page 15 of 27


281

REFERENCES

282

1.

283

a004978.

284

2.

285

collagen. Evidence for a role for hydroxyproline in stabilizing the triple-helix of collagen.

286

Biochem. Biophys. Res. Commun. 1973, 52, 115-20.

287

3.

288

fibrillar collagens in health and disease. Crit. Rev. Biochem. Mol. Biol. 2017, 52, 74-95.

289

4.

290

Blais, A. Hydrolyzed collagen improves bone metabolism and biomechanical parameters in

291

ovariectomized mice: an in vitro and in vivo study. Bone 2010, 46, 827-34.

292

5.

293

improve bone mineral density and bone markers in postmenopausal women-A randomized

294

controlled study. Nutrients 2018, 10, 97.

295

6.

296

fed a high-lipid and high-sucrose diet. Food Sci. Technol. Res. 2013, 19, 1149-1153.

297

7.

298

Abe, K.; Nakai, Y. Collagen peptide ingestion alters lipid metabolism-related gene expression

299

and the unfolded protein response in mouse liver. Br. J. Nutr. 2017, 117, 1-11.

300

8.

301

hydrolysate as a dipeptidyl peptidase IV inhibitor improves glycemic control in streptozotocin-

302

induced diabetic rats. J. Funct. Foods 2014, 11, 235-242.

Ricard-Blum, S. The collagen family. Cold Spring Harb. Perspect. Biol. 2011, 3,

Berg, R. A.; Prockop, D. J. The thermal transition of a non-hydroxylated form of

Gjaltema, R. A.; Bank, R. A. Molecular insights into prolyl and lysyl hydroxylation of

Guillerminet, F.; Beaupied, H.; Fabien-Soule, V.; Tome, D.; Benhamou, C. L.; Roux, C.;

Konig, D.; Oesser, S.; Scharla, S.; Zdzieblik, D.; Gollhofer, A. Specific collagen peptides

Koyama, Y. I.; Kusubata, M. Effects of collagen peptide ingestion on blood lipids in rats

Tometsuka, C.; Koyama, Y. I.; Ishijima, T.; Toyoda, T.; Teranishi, M.; Takehana, K.;

Huang, S. L.; Hung, C. C.; Jao, C. L.; Tung, Y. S.; Hsu, K. C. Porcine skin gelatin

15



Page 16 of 27

303

9.

Hsieh, C. H.; Wang, T. Y.; Hung, C. C.; Chen, M. C.; Hsu, K. C. Improvement of

304

glycemic control in streptozotocin-induced diabetic rats by Atlantic salmon skin gelatin

305

hydrolysate as the dipeptidyl-peptidase IV inhibitor. Food Funct. 2015, 6, 1887-92.

306

10.

307

purification of an ACE inhibitory peptide from sea cucumber gelatin hydrolysate. Process

308

Biochem. 2007, 42, 1586-1591.

309

11.

310

Morimatsu, F. Angiotensin I-converting enzyme-inhibitory peptides obtained from chicken

311

collagen hydrolysate. J. Agric. Food Chem. 2008, 56, 9586-91.

312

12.

313

antihypertensive properties of squid skin gelatin hydrolysates. Food Chem. 2012, 131, 225-230.

314

13.

315

identification in a porcine gelatin prolyl endoproteinase hydrolysate with angiotensin converting

316

enzyme (ACE) inhibitory and hypotensive activity. J. Funct. Foods 2017, 34, 77-88.

317

14.

318

A.; Kido, Y.; Nakabo, Y.; Ohtsuki, K. Identification of food-derived collagen peptides in human

319

blood after oral ingestion of gelatin hydrolysates. J. Agric. Food Chem. 2005, 53, 6531-6.

320

15.

321

Hydroxyproline-containing dipeptides and tripeptides quantified at high concentration in human

322

blood after oral administration of gelatin hydrolysate. Int. J. Food Sci. Nutr. 2010, 61, 52-60.

323

16.

324

hydroxyproline-containing peptides in blood using a protease digest of stable isotope-labeled

325

collagen. J. Agric. Food Chem. 2014, 62, 12096-102.

Zhao, Y.; Li, B.; Liu, Z.; Dong, S.; Zhao, X.; Zeng, M. Antihypertensive effect and

Saiga, A.; Iwai, K.; Hayakawa, T.; Takahata, Y.; Kitamura, S.; Nishimura, T.;

Lin, L.; Lv, S.; Li, B. Angiotensin-I-converting enzyme (ACE)-inhibitory and

O'Keeffe, M. B.; Norris, R.; Alashi, M. A.; Aluko, R. E.; FitzGerald, R. J. Peptide

Iwai, K.; Hasegawa, T.; Taguchi, Y.; Morimatsu, F.; Sato, K.; Nakamura, Y.; Higashi,

Ichikawa, S.; Morifuji, M.; Ohara, H.; Matsumoto, H.; Takeuchi, Y.; Sato, K.

Taga, Y.; Kusubata, M.; Ogawa-Goto, K.; Hattori, S. Highly accurate quantification of

16


Page 17 of 27


326

17.

Shigemura, Y.; Akaba, S.; Kawashima, E.; Park, E. Y.; Nakamura, Y.; Sato, K.

327

Identification of a novel food-derived collagen peptide, hydroxyprolyl-glycine, in human

328

peripheral blood by pre-column derivatisation with phenyl isothiocyanate. Food Chem. 2011,

329

129, 1019-24.

330

18.

331

hydroxyproline (Hyp)-Gly after oral administration of a novel gelatin hydrolysate prepared using

332

ginger protease. J. Agric. Food Chem. 2016, 64, 2962-70.

333

19.

334

enzymatic stability, intestinal permeability, and absorption of Gly-Pro-Hyp and Pro-Hyp. J.

335

Agric. Food Chem. 2016, 64, 7127-33.

336

20.

337

structures of hydroxyproline-containing peptides in human blood after oral ingestion of gelatin

338

hydrolysates from different sources. J. Agric. Food Chem. 2007, 55, 1532-5.

339

21.

340

E. Y.; Nakamura, Y.; Sato, K. Effect of Prolyl-hydroxyproline (Pro-Hyp), a food-derived

341

collagen peptide in human blood, on growth of fibroblasts from mouse skin. J. Agric. Food

342

Chem. 2009, 57, 444-9.

343

22.

344

Tajima, S. Collagen-derived dipeptide, proline-hydroxyproline, stimulates cell proliferation and

345

hyaluronic acid synthesis in cultured human dermal fibroblasts. J. Dermatol. 2010, 37, 330-8.

346

23.

347

Shimizu, J.; Wada, M.; Mano, H. Collagen-derived dipeptide prolyl-hydroxyproline promotes

Taga, Y.; Kusubata, M.; Ogawa-Goto, K.; Hattori, S. Efficient absorption of X-

Sontakke, S. B.; Jung, J. H.; Piao, Z.; Chung, H. J. Orally available collagen tripeptide:

Ohara, H.; Matsumoto, H.; Ito, K.; Iwai, K.; Sato, K. Comparison of quantity and

Shigemura, Y.; Iwai, K.; Morimatsu, F.; Iwamoto, T.; Mori, T.; Oda, C.; Taira, T.; Park,

Ohara, H.; Ichikawa, S.; Matsumoto, H.; Akiyama, M.; Fujimoto, N.; Kobayashi, T.;

Kimira, Y.; Ogura, K.; Taniuchi, Y.; Kataoka, A.; Inoue, N.; Sugihara, F.; Nakatani, S.;

17



Page 18 of 27

348

differentiation of MC3T3-E1 osteoblastic cells. Biochem. Biophys. Res. Commun. 2014, 453,

349

498-501.

350

24.

351

Wada, M.; Mano, H. Collagen-derived dipeptide prolyl-hydroxyproline promotes osteogenic

352

differentiation through Foxg1. Cell. Mol. Biol. Lett. 2017, 22, 27.

353

25.

354

Mano, H. Oral collagen-derived dipeptides, prolyl-hydroxyproline and hydroxyprolyl-glycine,

355

ameliorate skin barrier dysfunction and alter gene expression profiles in the skin. Biochem.

356

Biophys. Res. Commun. 2015, 456, 626-30.

357

26.

358

and plants. Food Chem. 2017, 228, 506-517.

359

27.

360

protein-derived hydrolyzates and peptides. Crit. Rev. Food Sci. Nutr. 2016, 56, 760-87.

361

28.

362

Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk.

363

J. Dairy Sci. 1995, 78, 777-83.

364

29.

365

and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. J. Dairy Sci.

366

1995, 78, 1253-7.

367

30.

368

enzyme (ACE) inhibitory peptides from Alaska pollack (Theragra chalcogramma) skin. Process

369

Biochem. 2001, 36, 1155-1162.

Kimira, Y.; Odaira, H.; Nomura, K.; Taniuchi, Y.; Inoue, N.; Nakatani, S.; Shimizu, J.;

Shimizu, J.; Asami, N.; Kataoka, A.; Sugihara, F.; Inoue, N.; Kimira, Y.; Wada, M.;

Lee, S. Y.; Hur, S. J. Antihypertensive peptides from animal products, marine organisms,

Saleh, A. S.; Zhang, Q.; Shen, Q. Recent research in antihypertensive activity of food

Nakamura, Y.; Yamamoto, N.; Sakai, K.; Okubo, A.; Yamazaki, S.; Takano, T.

Nakamura, Y.; Yamamoto, N.; Sakai, K.; Takano, T. Antihypertensive effect of sour milk

Byun, H. G.; Kim, S. K. Purification and characterization of angiotensin I converting

18


Page 19 of 27


370

31.

Kim, S. K.; Byun, H. G.; Park, P. J.; Shahidi, F. Angiotensin I converting enzyme

371

inhibitory peptides purified from bovine skin gelatin hydrolysate. J. Agric. Food Chem. 2001,

372

49, 2992-7.

373

32.

374

Therkildsen, M. Angiotensin I-converting enzyme-inhibitory peptides from bovine collagen:

375

insights into inhibitory mechanism and transepithelial transport. Food Res. Int. 2016, 89, 373-

376

381.

377

33.

378

T. Angiotensin I-converting enzyme inhibitory peptides in a hydrolyzed chicken breast muscle

379

extract. J. Agric. Food Chem. 2003, 51, 1741-5.

380

34.

381

Y.; Morimatsu, F. Blood concentration of food-derived peptides following oral intake of chicken

382

collagen hydrolysate and its angiotensin-converting enzyme inhibitory activity in healthy

383

volunteers. Nippon Shokuhin Kagaku Kogaku Kaishi 2009, 56, 326-330.

384

35.

385

activity

386

Chromatogr. 2010, 24, 312-7.

387

36.

388

enzyme inhibitory activity from complex natural colourants and foods using high-throughput

389

LC-MS/MS. Food Chem. 2011, 126, 1909-15.

390

37.

Fu, Y.; Young, J. F.; Rasmussen, M. K.; Dalsgaard, T. K.; Lametsch, R.; Aluko, R. E.;

Saiga, A.; Okumura, T.; Makihara, T.; Katsuta, S.; Shimizu, T.; Yamada, R.; Nishimura,

Iwai, K.; Zhang, Y.; Kouguchi, T.; Saiga-Egusa, A.; Shimizu, M.; Ohmori, T.; Takahata,

Geng, F.; He, Y.; Yang, L.; Wang, Z. A rapid assay for angiotensin-converting enzyme using

ultra-performance

liquid

chromatography-mass

spectrometry.

Biomed.

Inoue, K.; Kitade, M.; Hino, T.; Oka, H. Screening assay of angiotensin-converting

Dixon, M. The determination of enzyme inhibitor constants. Biochem. J. 1953, 55, 170-1.

19



Page 20 of 27

391

38.

Masuyer, G.; Akif, M.; Czarny, B.; Beau, F.; Schwager, S. L.; Sturrock, E. D.; Isaac, R.

392

E.; Dive, V.; Acharya, K. R. Crystal structures of highly specific phosphinic tripeptide

393

enantiomers in complex with the angiotensin-I converting enzyme. FEBS J 2014, 281, 943-56.

394

39.

395

with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010,

396

31, 455-61.

397

40.

398

hydroxyproline (Hyp)-containing cyclic dipeptides with high oral bioavailability: efficient

399

formation of cyclo(X-Hyp) from X-Hyp-Gly-type tripeptides by heating. J. Agric. Food Chem.

400

2017, 65, 9514-9521.

401

41.

402

Hyp-Gly-type tripeptides promote differentiation of MC3T3-E1 pre-osteoblasts. J. Funct. Foods

403

2018, 46, 456-462.

404

42.

405

digestibility of antihypertensive beta-casein tripeptides, Val-Pro-Pro and Ile-Pro-Pro, in the

406

gastrointestinal tract: analyses using an in vitro model of mammalian gastrointestinal digestion.

407

J. Agric. Food Chem. 2008, 56, 854-8.

408

43.

409

mechanism of an angiotensin I-converting enzyme inhibitory peptide derived from chicken

410

breast muscle. J. Agric. Food Chem. 2006, 54, 942-5.

411

44.

412

angiotensin I-converting enzyme (ACE)-inhibitory peptide derived from chicken collagen

Trott, O.; Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking

Taga, Y.; Kusubata, M.; Ogawa-Goto, K.; Hattori, S. Identification of collagen-derived

Taga, Y.; Kusubata, M.; Ogawa-Goto, K.; Hattori, S.; Funato, N. Collagen-derived X-

Ohsawa, K.; Satsu, H.; Ohki, K.; Enjoh, M.; Takano, T.; Shimizu, M. Producibility and

Saiga, A.; Okumura, T.; Makihara, T.; Katsuda, S.; Morimatsu, F.; Nishimura, T. Action

Iwai, K.; Saiga-Egusa, A.; Hayakawa, T.; Shimizu, M.; Takahata, Y.; Morimatsu, F. An

20


Page 21 of 27


413

hydrolysate lowers blood pressure in spontaneously hypertensive rats. Nippon Shokuhin Kagaku

414

Kogaku Kaishi 2008, 55, 602-605.

415

45.

416

Contribution of Leu and Hyp residues to antioxidant and ACE-inhibitory activities of peptide

417

sequences isolated from squid gelatin hydrolysate. Food Chem. 2011, 125, 334-341.

418

46.

419

enzyme inhibitory peptides by integrating in silico modeling and an in vitro assay.

420

ChemMedChem 2013, 8, 1057-66.

421

47.

422

inhibitory peptides derived from Alaskan pollack skin. J. Biochem. Mol. Biol. 2002, 35, 239-43.

423

48.

424

peptide substrates and inhibitors of angiotensin-converting enzyme. Importance of the COOH-

425

terminal dipeptide sequence. J. Biol. Chem. 1980, 255, 401-7.

426

49.

427

enzyme inhibitory peptides: quantitative structure-activity relationship study of di- and

428

tripeptides. J. Agric. Food Chem. 2006, 54, 732-8.

429

50.

430

Angiotensin converting enzyme inhibitory peptides from a lactotripeptide-enriched milk

431

beverage are absorbed intact into the circulation. J. Nutr. 2007, 137, 953-8.

432

51.

433

natural antihypertensive dipeptide can be absorbed into the human circulatory blood system.

434

Clin. Exp. Pharmacol. Physiol. 2002, 29, 204-8.

Alemán, A.; Giménez, B.; Pérez-Santin, E.; Gómez-Guillén, M. C.; Montero, P.

Jing, T.; Feng, J.; Li, D.; Liu, J.; He, G. Rational design of angiotensin-I-converting

Byun, H. G.; Kim, S. K. Structure and activity of angiotensin I converting enzyme

Cheung, H. S.; Wang, F. L.; Ondetti, M. A.; Sabo, E. F.; Cushman, D. W. Binding of

Wu, J.; Aluko, R. E.; Nakai, S. Structural requirements of Angiotensin I-converting

Foltz, M.; Meynen, E. E.; Bianco, V.; van Platerink, C.; Koning, T. M.; Kloek, J.

Matsui, T.; Tamaya, K.; Seki, E.; Osajima, K.; Matsumoto, K.; Kawasaki, T. Val-Tyr as a

21



Page 22 of 27

435

Figure captions

436

Figure 1. ACE inhibition rate of (A) GDCH and (B) H-GDCH. The data represent the mean ±

437

SD of three separate measurements.

438 439

Figure 2. Dixon plot of (A) Leu-Hyp-Gly and (B) Leu-Pro-Gly. The kinetic assays were

440

performed at substrate concentrations of (▲) 0.1 and (■) 1.0 mM. The data represent the mean ±

441

SD of three separate measurements.

442 443

Figure 3. Residual ratio of tripeptides after incubation with mouse plasma. Ala-Hyp-Gly, Leu-

444

Hyp-Gly, Ala-Pro-Gly, Leu-Pro-Gly, and Ile-Pro-Pro were incubated with freshly prepared

445

mouse plasma at 37 °C for 0, 15, 30, 60, and 90 min. The residual ratio was calculated using the

446

peak area of the respective peptides in LC–MS analysis. The data represent the mean ± SD (n =

447

3).

22


Page 23 of 27


Tables Table 1. ACE-inhibitory Activity of Collagen-derived Oligopeptides and Their Contents in GDCHs

a

Ala-Hyp-Gly Ala-Pro-Gly

IC50 (µM)a,c 151.3 ± 6.8 1293.3 ± 286.6

Content in GDCH (mg/g)b,c 2.205 ± 0.087 0.204 ± 0.008

Content in H-GDCH (mg/g)b,c 0.197 ± 0.017 0.056 ± 0.004

Glu-Hyp-Gly

404.5 ± 51.4

1.204 ± 0.057

0.310 ± 0.009

Ile-Hyp-Gly

9.4 ± 2.2

0.076 ± 0.002

0.018 ± 0.002

Leu-Hyp-Gly Leu-Pro-Gly Leu-Hyp

5.5 ± 1.5 373.8 ± 77.2 3462.1 ± 1012.2

1.857 ± 0.254 0.008 ± 0.001 ND

0.131 ± 0.018 0.002 ± 0.001 ND

Phe-Hyp-Gly

210.9 ± 37.1

0.380 ± 0.022

0.013 ± 0.001

Pro-Hyp-Gly Pro-Pro-Gly

257.8 ± 41.9 1372.6 ± 297.8

0.017 ± 0.001 ND

0.010 ± 0.004 ND

Ser-Hyp-Gly Ser-Pro-Gly

130.6 ± 4.5 1029.5 ± 163.0

0.183 ± 0.021 0.071 ± 0.003

ND ND

Val-Hyp-Gly Val-Pro-Gly

12.8 ± 0.7 125.9 ± 4.5

0.018 ± 0.001 0.093 ± 0.008

0.007 ± 0.001 0.037 ± 0.001

Ile-Pro-Pro 0.9 ± 0.2 The data were obtained by ACE inhibition assay using synthetic peptides. bThe data were

obtained by LC–MS analysis of the collagen hydrolysates. ND, not detected. cThe data represent the mean ± SD of three separate measurements.

23



Page 24 of 27

Figure Graphics Figure 1

24


Page 25 of 27


Figure 2

25



Page 26 of 27

Figure 3

26


Page 27 of 27


GRAPHICS FOR TABLE OF CONTENTS

27


Characterization of Angiotensin-Converting Enzyme Inhibitory Activity

Recommend Documents